Jiangsu Yahong Meditech Co., Ltd. (SHA:688176)

China · Delayed Price · Currency is CNY

12.73

-0.35 (-2.68%)

Sep 10, 2026, 1:45 PM CST

Market Cap	7.37B +8.3%
Revenue (ttm)	302.24M +20.3%
Net Income	-492.77M
EPS	-0.87
Shares Out	563.52M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,429,633
Open	13.16
Previous Close	13.08
Day's Range	12.63 - 13.16
52-Week Range	8.93 - 18.11
Beta	0.29
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 29, 2026

About Jiangsu Yahong Meditech

Jiangsu Yahong Meditech Co., Ltd., a pharmaceutical company, focuses on urogenital tumors and women's health in China and internationally. It develops APL-1702, a photodynamic drug-device combination product for the treatment of high-grade squamous intraepithelial lesions of the cervix and for HPV viral clearance; APL-2302, an oral small-molecule inhibitor of the deubiquitinating enzyme ubiquitin-specific protease 1 (USP1) for the treatment of ovarian and breast cancer; APL-2501 for the treatment of ovarian cancer; AT-018 for the treatment of b... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2010

Employees 497

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688176

Full Company Profile

Financial Performance

In 2025, Jiangsu Yahong Meditech's revenue was 277.12 million, an increase of 37.49% compared to the previous year's 201.56 million. Losses were -416.38 million, 8.41% more than in 2024.

Financial Statements